TP53 and cervical carcinoma: In this study, we explored the possibility of combining the natural product withferin A(WA) with the HDAC6 inhibitor ricolinostat (RIC) to treat cervical cancer cells, with afocus on the ubiquitination and acetylation of p53 and the consequences for its stability.These results suggested that the combination of WA and RIC is more effective than eithertreatment alone in inhibiting the degradation and increasing the stability of p53, therebysynergistically slowing the onset and progression of cervical cancer.